Chenghua Xia

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Mark J. Ratain, Tim Eisen, Walter M. Stadler et al. · Journal of Clinical Oncology · 2006 · 1K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

Axel Hauschild, Sanjiv S. Agarwala, Uwe Trefzer et al. · Journal of Clinical Oncology · 2009 · 545 citations · Full text

Medicine, Oncology, Pharmacology +15

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

Walter M. Stadler, Robert A. Figlin, David F. McDermott et al. · Cancer · 2010 · 253 citations

Medicine, Oncology, Pharmacotherapy +16

Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

David F. McDermott, Jeffrey A. Sosman, René González et al. · Journal of Clinical Oncology · 2008 · 249 citations

Medicine, Oncology, Pharmacotherapy +15

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

Keith T. Flaherty, Joan H. Schiller, Lynn M. Schuchter et al. · Clinical Cancer Research · 2008 · 146 citations · Full text

Medicine, Oncology, Pharmacology +17